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G
lycoproteins, as valuable targets for
dendritic cell (DC)-vaccination in
cancers, remain an open question. Glyco-
sylated structures, which are aberrantly
modified during cancerisation, impact
positively or negatively on glycoprotein
immunogenicity. Here is presented
an oncofetal glycovariant of bile-salt-
dependent-lipase, expressed on human
tumoral pancreas and efficiently pro-
cessed by DC’s, inducing T-lymphocyte
activation.
This mini-review presents recent findings
defining the interaction mechanisms
between glycosylated tumor-associated
antigen (TAA) and immune cells in order
to develop dendritic cell (DC) vaccination
in pancreatic ductal adenocarcinoma
(PDAC).
DC’s initiate and regulate T-cell immu-
nity and thus represents promising vectors
for the clinical development of cancer
vaccines. DC’s are endowed with two
critical features: subsets and functional
plasticity related to maturation state.
These features direct them to mount
functionally distinct types of responses.
Besides, the quality of CD4
+ T-cell
responses is guided by the nature of
the antigen. T cells, in addition to their
peptide-specific reactions, can also respond
to DC’s major histocompatibility complex
(MHC) class I- and II-restricted peptides
bearing motifs with post-translational
modifications that include phophorylation
and glycosylation (for a review see ref. 1).
Aberrant glycosylations can dramatically
lead the immune system to opposite issues.
They can be related to autoimmune
diseases where abnormally glycosylated
proteins activate effector T cells respons-
ible for autoimmune cytotoxic responses
or to cancers,
2 where T-cell activation
could be beneficial. Such an aberrant
glycosylation of cell surface mucins distin-
guishes neoplastic from normal cells.
Alteration in the glycan moiety, without
any change in the polypeptide backbone,
can then create neo-antigens on cells
and may affect their interaction with the
immune system. These onco-glycopeptides
are therefore challenging antigens, and
should encourage efforts on targeting of
tumor-specific glycopeptides, without the
risk of breaking tolerance to self. The
notion that glycopeptides may be then
recognized as foreign, while peptides,
although immunogenic, are perceived as
self is elegantly illustrated in a recent
report on the glycopeptides neoepitopes
derived from the most studied TAA,
mucin MUC-1.
3
DC’s are equipped with specialized
receptors, including Toll-like and lectin-
like receptors (for a review see ref. 4).
C-type lectin receptors recognize “specific”
carbohydrate structures and participate in
their detection during tumor progression,
as shown in human PDAC.
5 Carbohydrate
ligand receptors (CLRs), mannose receptor
(MR), DC-SIGN, and dectin-1, to name
but a few, are involved in glycan-mediated
pathogen recognition and internalization
of endogenous and exogenous antigen for
loading on MHC class I and II molecules
(for a review see ref. 6). Targeting antigen
to MR enhances humoral and cellular
responses and tumor-protective immune
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responses.
7 MR has also been demon-
strated to play an enhancer role in antigen
uptake and presentation since mannosy-
lated antigens are better internalized and
presented to T-cells.
8 However, depending
on the DCs activation state, antigen
presentation to T-cells might result in
immune activation or immune down-
regulation. For instance, high-mannose
structures on the cell wall target MR and
DC-SIGN to induce signaling, thus lead-
ing to the production of anti-inflammatory
cytokines such as IL-10.
6 Tumor-derived
mucins, probably interacting with MR or
other C-type lectin receptors on DC’s,
were shown to affect the differentiation
and maturation of monocyte DC’s. This
then results in antigen presenting cells
(APCs) with a tolerogenic/regulatory cyto-
kine profile.
9 Yet, the in vivo situation is
likely more complex; as shown by others,
semi-maturated DC’s remain responsive
to further signals in vitro and in vivo,
which converts their tolerogenicity into
immunogenicity.
10
Although the altered glycosylated tumor
antigens represent potential targets for
DC-based cancer immunotherapy, the
outcome of glycosylated antigen transport,
processing, and presentation to T-cells is
indeed far less explored than that of
peptidic antigens. Therefore, investiga-
tions of the interaction between tumor-
specific glycosylated antigen and CLRs
on APCs might explain why immune
responses against tumor glycans are in
general so difficult to obtain. They might
also lead to the development of protocols
that generate T-cells that are directed
against glycan-containing peptides.
4
We have studied interactions between
DC’s and the oncofetal fucose-rich glyco-
variantofbilesalt-dependentlipase(BSDL),
referred to as pathological BSDL carrying
the fucosylated J28 glycotope (pBSDL-
J28) because it is characterized by the
J28 monoclonal antibody (mAbJ28).
11
pBSDL-J28 is expressed on human
tumoral pancreas
12 and on human pan-
creatic tumor cell lines.
13 mAbJ28 recog-
nizes a carbohydrate-dependent antigenic
structure, termed J28 glycotope, located
within the O-glycosylated mucin-like
C-terminal domain of pBSDL-J28.
14
The formation of the J28 glycotope,
characterized by fucosylated O-linked side
chains, requires core2 b1,6 N-acetylglu-
cosaminyltransferase and a1,3/4 fucosyl-
transferase,
14 two glycosyltransferases
whose expression is upregulated during
pancreatic neoplastic processes.
15
We previously reported the presence
of circulating antibodies recognizing the
O-glycosylated C-terminal domain in
most type 1 diabetic patients and some
patients afflicted with PDAC,
16 which
may reflect the potential of this O-
glycosylated C-terminal domain to induce
humoral immunity. The expression of
pBSDL-J28 on pancreatic tumoral cells
and tissues and their immunogenic poten-
tial led us to hypothesize that this
glycotope may serve as DC’s target and
further lead to immunotherapy against
PDAC. We therefore investigated the
DC’s-processing of tumoral pancreatic
glycoprotein pBSDL-J28 and its outcome.
Figure1 shows that human immature
monocyte-derived DC’s (iMoDC) cap-
tures pBSDL-J28 as well as recombinant
C-terminal polypeptide-J28. pBSDL-J28
binds to MR (CD206) expressed on
iMoDC surface.
12 Thus, oligosaccharides
recognized by C-type lectin-like carbohyd-
rate recognition domains of MR termin-
ating in mannose, N-acetylglucosamine,
and/or fucose residues, the latter being
crucial elements of the J28 glycotope
structure for mAbJ28 recognition, can be
involved in DC’s binding (for a review
see ref. 17). However, we cannot rule out
that pBSDL-J28 binds to other receptors.
Binding results in the internalization
of pBSDL-J28 and its delivery into
MHC class II compartment (MIIC) and
late endosomes, where the Alexa 488-
labeled pBSDL-J28 (A488-pBSDL-J28)
processing products were detected.
A488-(glycosylated)-peptide epitopes co-
localized in lysosomes with LAMP-1
(CD107a) and in late endosomes with
HLA-DM. Thus, DC’s internalize tumo-
ral antigens mainly by receptor mediated-
endocytosis but also by macropinocytosis
(not shown here) to direct them to MIIC.
12
Hence pBSDL-J28 can be delivered
into the HLA class II pathway, as opposed
to MUC1 and HER2/Neu,
18 which
present structures that are differently
glycosylated. In PDAC, pBSDL-J28 car-
ries fucosylated O-linked branches whereas
tumoral MUC1 carries short O-glycans
such as T (Galb1–3GalNAca1-O-Ser/
Thr), Tn (GalNAca1-O-Ser/Thr), and
sialyl-Tn antigens (NeuAc-GalNAca1-O-
Ser/Thr).
5,19 Several apparently contradict-
ory reports have illustrated the complexity
of glycoantigen binding and internaliza-
tion. MUC1 binding and internalization
involve the presence of sialyl
19 and
GalNAc residue at terminal position,
5
which require SIGLECs and MGL recep-
tors respectively and can drastically change
the binding affinity of ligand to receptors.
These data confirm that the TAA glyco-
sylation pattern plays an important role in
antigen internalization, processing, glyco-
sylated epitope presentation, and sub-
sequent immune response.
3 Thus, in
addition to regulating cell-cell adhesion
and migration, the alteration of carbohy-
drates on the cell surface during carcino-
genesis might influence the interaction
with CLRs on resident APCs and direct
the response toward T-lymphocyte activa-
tion or inhibition.
4
Licensing of DC’s by CD40 ligation
remains the way to induce IL-12 produc-
tion and subsequent Th1 polarized res-
ponse, which is one of the objectives for
cancer vaccination. This proved promising
in our conditions as pulsing DC’s with
pBSDL-J28 C-terminal glycopolypeptide
and maturation with CD40L triggered
CD4 and CD8 T-cell proliferation as
shown in Figure2. Thus, DC’s could
use distinct endocytosis mechanisms to
simultaneously introduce pBSDL-J28 into
separate intracellular compartments, which
were dedicated to presentation to CD8
+ or
CD4
+ T cells. Interestingly, it has been
shown that the DC’s and macrophages
use only MR-endocytosed OVA antigen
for CD8
+ T cell activation, whereas
(macro)pinocytosed and scavenger recep-
tor-endocytosed OVA antigen were used
only for CD4
+ T-cell activation.
20 More-
over, DC’s pulsed with either synthetic
non-glycosylated pBSDL-C-terminal poly-
peptide or defucosylated pBSDL-J28 C-
terminal glycopolypeptide induced only
weak T-cell proliferation. This reduced
T cell proliferation provides evidence for
the pivotal implication of the fucose in
the epitope recognition. Thus, these data
highlight the existence of TCR(s) for
pBSDL-J28 fucosylated and O-glycosylated
C-terminal domain in the T-cell repertoire.
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The demonstration that pBSDL-J28 is
efficiently bound to DC MR, is also
internalized by macropinocytosis and is
further delivered to the MHC compart-
ments to mount CD4
+- and CD8
+-T cell
immunity makes it a potential mechanism
for the targeting of DC’s and the delivery
of tumor-associated epitopes for presenta-
tion. As long as TAA-specific immune
responses recently highlighted in prostate
and renal cancers
21 are considered as a
key parameter of efficacy, a major task
must be to improve DC vaccines. This
improved vaccine would be to elicit
antigen-specific CD4
+ and CD8
+ T cells
with high frequencies and high-quality and
to generate long-lived memory T cells, so
as to be clinically active.
Have glycopeptides a future in vaccine
therapies? Recent developments in the
synthesis of complex carbohydrates and
glycopeptides have made it possible to
construct glycoconjugate vaccine candi-
dates for evaluation in pre-clinical and
clinical trials. The Danishefsky team has
reported the synthesis Globo-H, Lewis y,
Lewis x, Lewis b, KH-1, MUC-1 and
the Tn, STn and TF-antigens. Several of
Figure1. Uptake of J28 glycosylated antigen
by iMoDC and intracellular localization.
(A) Alexa 488-labeled pBSDL-J28 (A488-
pBSDL-J28) and Alexa 488-labeled ovalbumin
(A488-OVA) uptakes were analyzed by
confocal laser microscopy. After 5-d culture,
iMoDC were loaded with A488-pBSDL-J28
(50 mg/mL) or A488-OVA (50 mg/mL) for 1h,
washed, fixed, and counterstained with CD1a
antibodies followed by mouse Alexa-594-
secondary antibodies. (B) Uptake of Alexa 488
recombinant C-terminal glycopolypeptide-
carrying J28 glycotope (A488-Cter-J28) by
iMoDC. iMoDC were incubated for 1h at 37°C
with A488-Cter-J28, washed, counterstained
with CD1a antibodies followed by mouse
Alexa-594-secondary antibodies, and
analyzed by confocal microscopy.
(C) Intracellular localization of A488-pBSDL-
J28. iMoDC were incubated for 1h at 37°C
with A488-pBSDL-J28 (50 mg/mL) and
counterstained with antibodies directed
against CD206, HLA-DR, HLA-DM, and
CD107a. Colocalization of each intracellular
marker (red) with A488-pBSDL-J28 (green) is
indicated in yellow. Original magnification
x630.
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the antigens have also been synthesized in
a clustered configuration in an attempt
to improve immunogenicity.
22 Thus far,
it appears that carbohydrate-conjugate
vaccines are well supported without any
auto-immune reactions. This is under-
scored when they are combined with
powerful additives such as saponin QS-
21 and the immunomodulator cyclophos-
phamide.
23 There are parallels between
vaccine-induced antibody responses and
the clinical course after immunization. Yet
it should be noted that high titers of the
high affinity IgG antibodies were difficult
to elicit in most patients. However, it is
Figure2. T-cell activation triggered by DC loaded with pBSDL-J28 C-terminal glycopolypeptide and exposed to CD40L (A) Proliferation of CD8
+ and CD4
+
T-lymphocytes. The histogram shows the proliferation of CD3
+ T-lymphocytes (left panel: CD8 T-lymphocytes; right panel: CD4
+ T-lymphocytes) cultured
with DC’s matured with CD40L and incubated without antigen, (upper panel), with pBSDL-J28 C-terminal glycopolypeptide (Cter-J28) (middle/high
panel), with defucosylated pBSDL-J28 C-terminal glycopolypeptide (Cter-Def) (middle/low panel), or with synthetic non-glycosylated pBSDL-C-terminal
polypeptide (Cter-Synt) (lower panel). (B) Similar increased percent of proliferating CD4
+ and CD8
+ T-lymphocytes after culture with mature MoDC loaded
with the pBSDL-J28 C-terminal glycopolypeptide, with defucosylated pBSDL-J28 C-terminal glycopolypeptide or with synthetic non-glycosylated pBSDL-
C-terminal polypeptide.
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now accepted that glycopeptides can
mediate classical MHC-mediated immune
responses. Thus, cytotoxic T lymphocytes
(CTL), which, as opposed to helper T-
cells, are expected to react with tumor
cells, present an additional opportunity for
glycopeptide-based cancer vaccines.
Because conventional therapy is ineffi-
cient for PDAC, the fourth leading cause
of cancer death in western countries,
immunotherapeutic approaches have
become tempting alternatives. Interest-
ingly, numerous studies demonstrate that
the clinical efficacy of different therapeutic
modalities, including radiotherapy and
chemotherapy, such as anthracyclins, Ab
therapy such as Herceptin (anti-Her-2/neu
mAb) and ipilimumab (anti-CTLA-4
antibody) and other drugs such as
Sunitinib (which seems to inhibit STA3)
and Imatinib (kinase inhibitor) is influ-
enced by the immune system (for a review
see refs. 24 and 25). Thus combinations
of different treatments with DC vaccines
might become efficient in a synergistic
manner. Also, delivering tumor antigens
directly to DC’s in vivo using antibodies,
targeting specific DC surface receptors,
constitutes a new approach to vaccination.
The pioneer studies in mice demonstrate
that potent antigen-specific helper CD4
+
and IFNc-CD8
+ T-cell immunity are
triggered in vivo by specific delivery of
antigen to DC’s.
26 Such a utilization of
immunostimulatory ligands to restore
DC’s functions in tumors is currently
applied to humans (for a review see ref.
28).
27
The fact that the majority of cell
proteins are glycosylated, and that pro-
tein glycosylation is known to be dysre-
gulated in cancer cells, should encourage
more effort on the targeting of tumor-
specific glycopeptides. In view of thera-
peutic advantages within combined treat-
ment protocols, understanding the
interaction mechanisms between glycosy-
lated TAA and DC’s shows the way for
further strategies to induce appropriate
Th1 immune responses against onco-
glycosylated antigen-bearing tumor cells.
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